National Securities Initiates Coverage on SciClone Pharmaceuticals (SCLN) with a Buy
More News related to SCLN
- SciClone (SCLN) Announces Enrollment for Phase 2 SCV-07 Complete
- SciClone Announces Enrollment Completion in Phase 2 Oral Mucositis Trial of SCV-07
- SciClone Pharmaceuticals to Present at the Piper Jaffray Annual Healthcare Conference
- SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings
- National Securities Initiates Coverage on SciClone Pharmaceuticals (SCLN) with a Buy
More News related to New Coverage
- Collins Stewart Initiates Coverage on Expedia (EXPE) with a Buy
- Collins Stewart Initiates Coverage on Priceline.com (PCLN) with a Hold; Limited Upside to Current Valuation
- FBR Capital Starts SolarWinds (SWI) at Outperform
- Thomas Weisel Starts Lexicon (LXRX) at Overweight, $2.50 Price Target
- Wells Fargo Initiates Coverage on THQ Inc. (THQI) with a Market Perform
National Securities initiates coverage on SciClone Pharmaceuticals (Nasdaq: SCLN) with a Buy. Price target $5.
To see more analyst ratings on SCLN Click Here.
SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in China and internationally.
Related Categories
New CoverageStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
